A Phase II Randomized Controlled Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Aug 2024 Results of secondary analysis assessing Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma published in the Head and Neck
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.
- 16 Nov 2020 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.